A researcher whose work was integral to the development of the Alzheimer’s drug simufilam has been found by the City University of New York to have engaged in “egregious misconduct” involving more than 20 scientific papers, Science reported.
Scientists are calling for stage 3 clinical trials of an Alzheimer s drug to be scrapped after a report highlighted serious doubts about the legitimacy of research that helped the medicine reach that stage.